Singular Genomics Announces Updated Presentation Time at the Inaugural Gilmartin Group Emerging Growth Company Showcase
Singular Genomics Systems, Inc. (Nasdaq: OMIC) has updated the time for its presentation at the Inaugural Gilmartin Group Emerging Growth Company Showcase. The presentation is now scheduled for 1:30 p.m. PT on Wednesday, August 31, 2022. Interested parties can register and access a live webcast of the event via a provided link. Singular Genomics is focused on developing next-generation sequencing and multiomics technologies, including the G4 Sequencing Platform, designed to deliver fast and accurate genomic results.
- Scheduled presentation at the Inaugural Gilmartin Group Emerging Growth Company Showcase highlights company visibility.
- Focus on next-generation sequencing and multiomics technologies suggests potential for growth in the life sciences sector.
- None.
Presentation now scheduled for 1:30 p.m. PT on Wednesday, August 31, 2022
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced its presentation time at the Inaugural Gilmartin Group Emerging Growth Company Showcase has been updated.
The new time for the presentation is 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day as previously scheduled, Wednesday, August 31, 2022. Investors and other interested parties are invited to register and access a live webcast of the presentation by following this link. Following the event, an archived webcast of the presentation will be available at investor.singulargenomics.com under Presentations & Events.
About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine.
Investor Contact
Matt Clawson
949-370-8500
ir@singulargenomics.com
Media Contact
Dan Budwick, 1AB
973-271-6085
dan@1abmedia.com
FAQ
What is the date and time of the Singular Genomics presentation at the Gilmartin Group Showcase?
How can I access the webcast of Singular Genomics' presentation?
What is the ticker symbol for Singular Genomics Systems?
What technologies does Singular Genomics develop?
